Pasireotide for postoperative pancreatic fistula

New England Journal of Medicine

Volumn 370, Issue 21, 2014, Pages 2014-2022

  Allen, Peter J ^a   Gon̈en, Mithat ^a   Brennan, Murray F ^a   Bucknor, Adjoa A ^a   Robinson, Lindsay M ^a   Pappas, Marisa M ^a   Carlucci, Kate E ^a   D'Angelica, Michael I ^a   DeMatteo, Ronald P ^a   Kingham, T Peter ^a   Fong, Yuman ^a   Jarnagin, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PASIREOTIDE; PLACEBO;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DILATED PANCREATIC DUCT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; PANCREAS ABSCESS; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS FUNCTION DISORDER; PANCREAS RESECTION; PANCREATIC LEAK; PANCREATICODUODENECTOMY; PANCREATITIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; VOMITING;

ABDOMINAL ABSCESS; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC DUCTS; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; SOMATOSTATIN;

EID: 84901049496     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1313688     Document Type: Article

References (21)

1. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999;125:250-6. (Pubitemid 29168810)
2. Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-210.
3. Butturini G, Daskalaki D, Molinari E, Scopelliti F, Casarotto A, Bassi C. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008;15:247-51. (Pubitemid 351818762)
4. Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 2008;207:490-8.
5. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003;196:954-64. (Pubitemid 36676558)
6. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580-8.
7. Tran K, Van Eijck C, Di Carlo V, et al. Occlusion of the pancreatic duct versus pancreaticojejunostomy: a prospective randomized trial. Ann Surg 2002;236:422-8.
8. Knaebel HP, Diener MK, Wente MN, Büchler MW, Seiler CM. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 2005;92:539-46. (Pubitemid 40685647)
9. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL. Postoperative morbidity and mortality of pancreaticoduodenectomy for periampullary cancer. Eur J Surg 1996;162:477-81.
10. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001;88:190-9. (Pubitemid 32142703)
11. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997;226:632-41. (Pubitemid 28049659)
12. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419-29.
13. Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 2003;196:556-64.
14. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16. (Pubitemid 34552506)
15. Fu Q, Berbée M, Wang W, et al. Preclinical evaluation of Som230 as a radiation mitigator in a mouse model: postexposure time window and mechanisms of action. Radiat Res 2011;175:728-35.
16. Fu Q, Berbée M, Boerma M, Wang J, Schmid HA, Hauer-Jensen M. The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival after totalbody irradiation by inhibiting exocrine pancreatic secretion. Radiat Res 2009;171:698-707.
17. Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg 2007;204:356-64. (Pubitemid 46283487)
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13. (Pubitemid 38963009)
19. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery 2005;138:8-13. (Pubitemid 40933766)
20. Koti RS, Gurusamy KS, Fusai G, Davidson BR. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010;12:155-65.
21. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54. (Pubitemid 26030676)